Randomised phase II trial of pegylated liposomal doxorubicin (DOXILR/CAELYXR) versus doxorubicin in the treatment of advanced or metastatic sift tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group

2.50
Hdl Handle:
http://hdl.handle.net/10541/83378
Title:
Randomised phase II trial of pegylated liposomal doxorubicin (DOXILR/CAELYXR) versus doxorubicin in the treatment of advanced or metastatic sift tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group
Authors:
Judson, Ian R; Radford, John A ( 0000-0001-7898-2786 ) ; Harris, Maggie A; Blay, Jean-Yves; Van Hoesel, Q; Le Cesne, A; Van Oosterom, A; Clemons, Mark; Kamby, C; Hermans, C; Whittaker, J; Donato di Paola, E; Verweij, Jaap; Nielsen, S
Affiliation:
Royal Marsden Hospital, London, UK
Citation:
Randomised phase II trial of pegylated liposomal doxorubicin (DOXILR/CAELYXR) versus doxorubicin in the treatment of advanced or metastatic sift tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. 2001, 37(7) : 870-877 Eur J Cancer
Journal:
European Journal of Cancer
Issue Date:
May-2001
URI:
http://hdl.handle.net/10541/83378
DOI:
10.1016/S0959-8049(01)00050-8
Type:
Article
Language:
en
ISSN:
09598049
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorJudson, Ian R-
dc.contributor.authorRadford, John A-
dc.contributor.authorHarris, Maggie A-
dc.contributor.authorBlay, Jean-Yves-
dc.contributor.authorVan Hoesel, Q-
dc.contributor.authorLe Cesne, A-
dc.contributor.authorVan Oosterom, A-
dc.contributor.authorClemons, Mark-
dc.contributor.authorKamby, C-
dc.contributor.authorHermans, C-
dc.contributor.authorWhittaker, J-
dc.contributor.authorDonato di Paola, E-
dc.contributor.authorVerweij, Jaap-
dc.contributor.authorNielsen, S-
dc.date.accessioned2009-10-02T15:26:51Z-
dc.date.available2009-10-02T15:26:51Z-
dc.date.issued2001-05-
dc.identifier.citationRandomised phase II trial of pegylated liposomal doxorubicin (DOXILR/CAELYXR) versus doxorubicin in the treatment of advanced or metastatic sift tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. 2001, 37(7) : 870-877 Eur J Canceren
dc.identifier.issn09598049-
dc.identifier.doi10.1016/S0959-8049(01)00050-8-
dc.identifier.urihttp://hdl.handle.net/10541/83378-
dc.language.isoenen
dc.subjectSoft Tissue Sarcomaen
dc.subjectDoxorubicinen
dc.subjectLiposomal Doxorubicinen
dc.subjectRandomized Phase II Trialen
dc.titleRandomised phase II trial of pegylated liposomal doxorubicin (DOXILR/CAELYXR) versus doxorubicin in the treatment of advanced or metastatic sift tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Groupen
dc.typeArticleen
dc.contributor.departmentRoyal Marsden Hospital, London, UKen
dc.identifier.journalEuropean Journal of Canceren
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.